Secarna Pharmaceuticals, a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, today announced that the company has entered into a co-development agreement with Firebrand Therapeutics, Inc., a research and development company focusing on cancer metastasis.…